Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 clinical study of Covigenix

Next Previous
X
Search
Trial Profile

A Phase 1 clinical study of Covigenix

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 29 Oct 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Covigenix VAX 001 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors Entos Pharmaceuticals

    • Most Recent Events

    • 29 Oct 2020 New trial record
    • 23 Oct 2020 According to an Entos Pharmaceuticals media release, NRC IRAP's support will help progress the company's COVID-19 DNA vaccine research to phase 1 human clinical trial to assess its safety at the Clinical Trials Research Center at the Canadian Center for Vaccinology (CCfV) in Nova Scotia, Canada.
    • 23 Oct 2020 According to an Entos Pharmaceuticals media release, the company announced that it is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) as part of the Government of Canada's continuing support for the development of domestic COVID-19 vaccine candidates.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top